Vivos Therapeutics (VVOS) Q1 2026: Revenue Jumps 70% as Sleep Center Pivot Drives Patient Growth

2026-05-21 | By EarningsIQ Research

Vivos Therapeutics delivered a 70% revenue surge in Q1 2026, driven by its strategic pivot to direct sleep center operations and away from legacy dentist enrollments. The company’s integration of Sleep Center of Nevada (SCN) and focus on in-network provider expansion fueled a sharp rise in patient appointments and gross margin, but costs and capital needs remain key watchpoints. With new specialty partnerships and pediatric programs launching, Vivos’ business model transformation is gaining traction, though execution and funding risks persist.

Summary

• Sleep Center Model Validated: Patient visits and revenue sharply increased as SCN integration accelerated growth.
• Margin Expansion Emerges: Gross margin improvement reflects higher value service mix and operating leverage.
• Specialty Partnerships Ahead: New medical affiliations and pediatric programs set to broaden addressable market.

Business Overview

Vivos Therapeutics develops and delivers oral appliance therapies and related clinical services for the treatment of obstructive sleep apnea (OSA) and other sleep disorders. The company generates revenue through a mix of diagnostic testing, patient treatment services at company-owned and affiliated sleep centers, and sales of oral appliances and tooth positioners. Major segments now include direct sleep center operations—anchored by the Sleep Center of Nevada (SCN) acquisition—supplemented by legacy sales to Vivos Integrated Provider (VIP) dentists and new specialty medical partnerships.

Performance Analysis

Vivos’ Q1 2026 results mark a decisive break from its legacy dentist-driven model, as SCN and affiliated sleep center operations now dominate revenue generation. Revenue leapt 70% year-over-year, propelled by a $2 million increase in sleep testing services and $900,000 in new OSA patient treatments at SCN. This expansion was only partially offset by a drop in appliance sales to VIP dentists and the cessation of new VIP enrollments, which are now immaterial to the business.

Gross profit more than doubled, with gross margin climbing 10 percentage points to 60%, reflecting the higher-margin nature of direct clinical services. Patient appointments surged 72% sequentially, and myofunctional therapy visits rose 43%, signaling broad-based demand for Vivos’ integrated care platform. However, general and administrative expenses nearly doubled due to SCN staffing, treatment center ramp-up, and non-recurring professional fees, leading to continued operating cash outflows and underscoring the need for further cost discipline and capital infusions.

• Direct Care Shift: SCN and affiliated centers now drive the majority of revenue, reducing dependence on legacy dentist channels.
• Operational Leverage Emerging: Flat salaries and wages versus prior quarter despite higher revenue point to early operating efficiency gains.
• Cash Burn Remains a Constraint: Operating cash outflows and ongoing capital needs highlight the urgency of cost controls and debt restructuring.

While top-line momentum is clear, the company’s ability to convert growth into sustainable profitability and positive cash flow remains a critical test for 2026.

Executive Commentary

Strategic Positioning

1. Direct-to-Patient Sleep Center Model

Vivos’ acquisition and integration of SCN has fundamentally shifted its revenue base from dentist enrollments to direct clinical services, allowing for greater control over patient pathways, payer relationships, and margin structure. Facility expansions and provider onboarding in Nevada are designed to unlock additional capacity and revenue per site.

2. In-Network Insurance Access and Provider Productivity

Expanding in-network insurance coverage is a central lever for patient conversion and revenue growth. The company’s alignment with a national firm for payer contracts aims to accelerate out-of-state expansion and reduce the headwinds experienced in Nevada. Enhanced provider training and experience are driving higher daily production and treatment acceptance rates.

3. Specialty Medical Partnerships and Pediatric Program

Vivos is leveraging strong inbound interest from cardiologists and other specialists to extend its model into new referral channels. Affiliations with large specialty practices and the launch of a high-margin pediatric OSA program are positioned to further diversify revenue and improve contribution margins.

4. Cost Discipline and Capital Structure

Management is pursuing debt restructuring and cost containment to address persistent cash burn. Non-recurring professional fees and increased G&A from integration activities are expected to normalize as the business scales, but near-term liquidity remains a watchpoint.

Key Considerations

This quarter’s results confirm the early traction of Vivos’ sleep center strategy, but the company remains in the midst of a transformation that requires execution across clinical, operational, and financial fronts.

Key Considerations:

• Provider Capacity Bottlenecks: Demand outpaces current provider availability, requiring ongoing hiring and training to fully capture patient volume.
• Payer Network Expansion: National insurance contracting is expected to streamline patient access and accelerate new market entry.
• Legacy Revenue Model Sunset: VIP dentist enrollments and deferred revenue are now negligible, removing an old dependency but also eliminating a historical revenue stream.
• Pediatric and Insomnia Programs: New service lines with attractive margins are set to launch, potentially boosting revenue per site and diversifying the patient base.

Risks

Vivos faces material risks from ongoing operating losses, capital requirements, and the challenge of scaling provider capacity to meet demand. Execution on payer contracting, integration of new centers, and the ability to realize projected margin gains are critical. Failure to secure additional financing or restructure debt could threaten NASDAQ compliance and operational continuity. Competitive pressure from established CPAP therapies and reimbursement dynamics also pose ongoing headwinds.

Forward Outlook

For Q2 2026, Vivos expects continued sequential growth in patient appointments and revenue as expanded provider days and in-network insurance coverage take effect. For full-year 2026, management projects normalized profit margins in established sites by year-end and revenue acceleration from specialty partnerships and pediatric program launches.

• Near-term revenue growth to be driven by SCN expansion, new provider onboarding, and payer network access
• Full-year profitability targeted at the practice level, with company-wide margin ramping as scale is achieved

Management highlighted that margin improvement will be a ramp, not a step function, with steady-state profitability expected in established markets by the end of 2026.

• Integration of national insurance contracts to support multi-state expansion
• Pediatric program revenue contribution expected to begin in July

Takeaways

Vivos’ Q1 results confirm the business model pivot is gaining traction, but the path to sustainable profitability remains under construction.

• Model Validation: Direct sleep center operations and in-network insurance access are driving rapid revenue and patient growth, but require continued execution on provider capacity and payer contracting.
• Margin Story Developing: Early gross margin gains are emerging, but full profitability depends on scaling new service lines and containing G&A as integration matures.
• Funding and Expansion Watch: Investors should monitor capital raises, debt restructuring progress, and the pace of specialty partnership launches as key catalysts for the next phase of growth.

Conclusion

Vivos’ transformation from a dentist enrollment business to an integrated sleep center operator is delivering tangible revenue and margin gains, with new clinical programs and specialty partnerships poised to broaden its market footprint. Sustained execution on provider expansion, payer integration, and capital management will determine whether early momentum can be translated into durable, cash-flow-positive growth.

Industry Read-Through

Vivos’ results highlight a broader shift in the sleep and respiratory care market toward integrated, multi-disciplinary service models and away from single-channel device sales. The rapid uptake of in-network, direct-to-patient clinical services—combined with the launch of pediatric and comorbidity-focused programs—signals growing demand for comprehensive, outcomes-driven care. For peers in sleep medicine and dental therapeutics, the emphasis on payer access, specialty referrals, and margin-rich ancillary services is likely to accelerate, especially as CPAP alternatives gain regulatory and clinical validation. Investors should watch for further consolidation and partnership activity as the sector adapts to value-based care and diversified patient pathways.

VVOS Healthcare Sleep Therapy Clinical Services Payer Integration Pediatric Program Margin Expansion